BeOne Medicines (ONC) Long-Term Deferred Tax (2016 - 2023)
BeOne Medicines (ONC) posted quarterly Long-Term Deferred Tax of $2.0 billion for Q4 2023, down 2.38% year-over-year from $2.1 billion in Q4 2022, and down 2.38% quarter-over-quarter from $2.1 billion in Q4 2022.
BeOne Medicines (ONC) Long-Term Deferred Tax (2016 - 2023) Analysis & Trends
BeOne Medicines (ONC) has reported Long-Term Deferred Tax for 8 consecutive years, with $2.0 billion the latest figure, recorded in Q4 2023.
- In Q4 2023, Long-Term Deferred Tax fell 2.38% year-over-year to $2.0 billion; the TTM figure through Dec 2023 stood at $2.0 billion (down 2.38% YoY), while the FY2023 annual figure was $2.0 billion, down 2.38% from the prior year.
- Long-Term Deferred Tax eased to $2.0 billion in Q4 2023 per ONC's latest filing, from $2.1 billion in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $2.1 billion in Q4 2022 and bottomed at $30.5 million in Q1 2019.
- Historically, Long-Term Deferred Tax has averaged $328.5 million across 5 years, with a median of $66.0 million in 2020.
- Annual changes were most pronounced in 2019 — Long-Term Deferred Tax surged 155.83% — and 2023, when it fell 2.38%.
- BeOne Medicines' Long-Term Deferred Tax stood at $37.9 million in 2019, then surged by 74.07% to $66.0 million in 2020, then surged by 61.98% to $106.8 million in 2021, then surged by 1846.59% to $2.1 billion in 2022, then slipped by 2.38% to $2.0 billion in 2023.
- Business Quant data shows ONC's Long-Term Deferred Tax at $2.0 billion in Q4 2023, $2.1 billion in Q4 2022, and $103.4 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 2.03 Bn |
| Dec 31, 2022 | 2.08 Bn |
| Jun 30, 2022 | 103.43 Mn |
| Mar 31, 2022 | 115.76 Mn |
| Sep 30, 2021 | 106.84 Mn |
| Jun 30, 2021 | 79.75 Mn |
| Mar 31, 2021 | 78.22 Mn |
| Dec 31, 2020 | 65.96 Mn |
| Sep 30, 2020 | 48.01 Mn |
| Jun 30, 2020 | 39.80 Mn |
| Mar 31, 2020 | 37.94 Mn |
| Dec 31, 2019 | 37.89 Mn |
| Sep 30, 2019 | 42.15 Mn |
| Jun 30, 2019 | 31.39 Mn |
| Mar 31, 2019 | 30.53 Mn |
| Dec 31, 2018 | 29.54 Mn |
| Sep 30, 2018 | 16.47 Mn |
| Jun 30, 2018 | 16.07 Mn |
| Mar 31, 2018 | 11.99 Mn |
| Dec 31, 2017 | 7.68 Mn |